IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER

Biliary Tract Neoplasms

National Cancer Institute (NCI)monoclonal_antibodyPhase 2Dormant

66/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 52/ 100
Competitive Position: 89/ 100

Competitive context

10 Active assets in the Biliary Tract Neoplasms cohort.

Asset / Sponsor	Phase	Rating
Durvalumab National Cancer Institute (NCI)	Phase 2	BB
Docetaxel ARCAGY/ GINECO GROUP	Phase 2	B
Shr-A1811 Haihua Yuan	Phase 2	CCC
FULVESTRANT Seagen, a wholly owned subsidiary of Pfizer	Phase 2	CCC
TRASTUZUMAB Seagen, a wholly owned subsidiary of Pfizer	Phase 2	CCC

View all 12 →

Same molecule, other indications

IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER is also rated in:

malignant pancreatic neoplasmDormant

Indicative ·

68 / 100

View asset →

Borderline Resectable Pancreatic Ductal AdenocarcinomaDormant

Indicative ·

66 / 100

View asset →

pancreatic ductal adenocarcinomaDormant

Indicative ·

66 / 100

View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →